Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Thursday, November 28, 2024 in observance of Thanksgiving. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Diabetes & prediabetes

First, know the risk with earlier diagnostic insight

As obesity rates continue to rise and the US contends with a growing aging population, the need for diabetes risk identification, prevention, and management is more critical than ever.1

Quest Diagnostics offers a comprehensive array of laboratory testing for diabetes to help you manage the disease in all of your patients, no matter where they are on the care continuum, ensuring continuity of care.

Identify insulin resistance, metabolic syndrome, prediabetes, and diabetes risk early—and in more patients—to help prevent or slow progression of the disease.

Learn more about early diagnostic insights

Learn more about diabetes and prediabetes risk

Start the right treatment plan with a differential diagnosis that goes beyond diabetes type 1 and type 2, including latent autoimmune diabetes in adults (LADA) and monogenic diabetes (MODY).

Learn more about making a differential diagnosis

Rely on our testing based on guidelines issued by the American Diabetes Association (ADA) to effectively monitor and manage diabetes patients and help them delay or avoid the potential for complications.

Learn more about monitoring diabetes

Defining the intersection of chronic conditions: a prevention-focused approach to cardiometabolic disease

With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.

Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.

  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,2 stage 4-5 CKD,3 and NAFLD.4
  • Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.5
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.6 The leading causes of end-stage renal disease are diabetes and hypertension.7
  • More than 75% of those who have T2DM have NAFLD.8

A comprehensive range of testing

Early diagnostic insights
Diabetes risk and prediabetes
Type 1 diabetes
Differential diagnosis
Newly diagnosed and
patient monitoring

The power of Quest

CDC-backed prevention program

Our preventive approach includes a commitment to the CDC’s National Diabetes Prevention Program (NDPP), a lifestyle intervention program administered nationwide by local hospitals, healthcare centers, and community organizations. This year-long program teaches patients with prediabetes to make lasting lifestyle changes that can improve or reverse their condition.

Patient adherence tools

Patient adherence and compliance are critical, no matter what the condition. But for diabetes in particular, the impact can be significant because patients play such a large role in the management of their disease. We offer an array of simple and effective tools to help your patients stay organized and motivated, so they can keep up with the many demands of diabetes.

Access to medical experts

We are committed to helping you deliver the best possible care to your patients. That’s why Quest Diagnostics has over 600 MDs, PhDs, and genetic counselors across the country who are available for consultations to help advise you on test selection and results interpretation.

Comprehensive range of testing

Our innovative diabetes tests and panels help you take a proactive approach to preventing, diagnosing, and managing diabetes. We have the tests you need to meet the full spectrum of patient needs.


 

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.    
 

References

  1. CDC. Maps of diagnosed diabetes and obesity in 1994, 2000, and 2015. Published April 2017. Accessed July 18, 2018. www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf
  2. Einarson,TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(83). doi: 10.1186/s12922-018-0728-6
  3. Benjamin EJ, Virani SS, Callaway CW, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492. doi:10.1161/CIR.0000000000000558
  4. Golabi P, Fukui N, Paik J, et al. Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2019;3(8):1050-1060. doi: 10.1002/hep4.1387
  5. Fox CS, Sullivan L, D’Agostino R, et al. The significant effect of diabetes duration on coronary heart disease mortality. Diabetes Care. 2004;27(3):704-708. doi:10.2337/diacare.27.3.704
  6. Penn MS, Klemes AB. Multimarker approach for identifying and documenting mitigation of cardiovascular risk. Future Cardiol. 2013;9(4):497-506. doi:10.2217/fca.13.27
  7. Ikonomidis I, Mihalakeas CA, Lekakis J, et al. Multimarker approach in cardiovascular risk prediction. Dis Markers. 2009;26(5-6):273-285. doi:10.3233/DMA-2009-0633
  8. Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011; 9(3): 321–328. doi:10.1586/erc.11.15

Get ahead of type 2 diabetes risk

Take a proactive approach to preventing, diagnosing, and managing diabetes at every stage of your patients’ care with the help of diagnostic insights.

Learn More

Diabetes & prediabetes

Resources

Physician resources

Patient adherence tools

 

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.